BioPorto CEO: We have to execute our strategy
Diagnostics company BioPorto kicked off the year in style last week, presenting top line growth of 58% for Q1. According to CEO Peter Mørch Eriksen, there are several elements to notice in the report.
by Benjamin Werner Christensen
A deficit of DKK 3.6 million from total revenue of DKK 4.8 million – that was the financial result for Danish diagnostics company BioPorto in Q1 of 2014. A result in line with the company’s guidance for the full year, according to which the company expects revenue of DKK 19-23 million and a deficit of DKK 10-14 million.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”It’s not like I’m leaving in tears today”
For abonnenter
BioPorto loses crucial patent trial
For abonnenter
BioPorto in court settlement and Abbott-alliance
For abonnenter
